| Sandra A. Gardiner |
Sandra A. Gardiner is currently the Chairman at Valley Humane Society, Director at Levitasbio, Inc., Chief Financial & Accounting Officer at Nektar Therapeutics, Partner at FLG Partners LLC, and Chief Financial Officer at Kronos Bio, Inc. She previously held positions such as Director-Finance & Human Resources at Cardima, Inc., CFO, Director & Vice President at Bend Research, Inc., Independent Director at Lucira Health, Inc., CFO & Vice President at Aspira Women's Health, Inc., CFO & Vice President at Lipid Sciences, Inc., CFO & Executive Vice President at Cutera, Inc., CFO & Secretary at TRIA Beauty, Inc., CFO & Secretary at Aptus Endosystems, Inc., CFO at Asante Solutions, Inc., CFO, Treasurer & Executive Vice President at Pulse Biosciences, Inc., Senior Accountant at Abbott Cardiovascular Systems, Inc., and CFO at Ventus Medical, Inc. She received her undergraduate degree from the University of California, Davis. |
| Jennifer Ruddock |
Jennifer Ruddock is currently the Director at the California Life Sciences Association and the Director at the San Francisco Foster Youth Fund. She previously served as the Chief Business Officer at Nektar Therapeutics. Ms. Ruddock completed her undergraduate degree at Colgate University in 1991. |
| Mark A. Wilson |
Mark A. Wilson is currently working as the Secretary, Chief Legal Officer & Senior VP at Nektar Therapeutics since 2002. He is also a Member at The State Bar of California. Previously, he worked as an Associate at Reed Associates, Inc. Mr. Wilson has a graduate degree from Seton Hall University School of Law and an undergraduate degree from Ernest Mario School of Pharmacy. |
| Jonathan Zalevsky |
Jonathan Zalevsky is currently a Director at ReAlta Life Sciences, Inc. He is also an Independent Director at Invea Therapeutics, Inc. since 2021. Prior to his current positions, he served as the Chief Research & Development Officer at Nektar Therapeutics starting in 2015. Previously, he worked at Takeda Pharmaceuticals U.S.A., Inc. as the Global VP & Head-Inflammation Drug Discovery Unit. Dr. Zalevsky holds a doctorate degree from The University of California, San Francisco and an undergraduate degree from the University of Colorado Boulder. |
| Mary A. Tagliaferri |
Mary A. Tagliaferri was the founder of Bionovo, Inc. (founded in 2002) where she held the title of President, Secretary, Treasurer & Director from 2011 to 2012. She is currently working as an Independent Director at Enzo Biochem, Inc. (since 2020), as a Director at Y-mAbs Therapeutics, Inc. (since 2024), and as the Chief Medical Officer & Senior Vice President at Nektar Therapeutics (since 2015). In her former positions, she worked as a Director at Atossa Therapeutics, Inc., as an Independent Director at Rayzebio, Inc. (from 2021 to 2024), as the Secretary, Treasurer & Chief Regulatory Officer at Lighten Up Enterprises International, Inc., and as the Chief Medical Officer at Kanglaite USA, Inc. (from 2012 to 2014). Dr. Tagliaferri obtained her undergraduate degree from Cornell University in 1988, her doctorate degree from The University of California, San Francisco in 2002, and her graduate degree from the American College of Traditional Chinese Medicine in 1995. |
| Robert B. Chess |
Robert B. Chess founded Penederm, Inc. in 1986, where he worked as President from 1986 to 1989 and Biota Technology, Inc. in 2013, where he worked as Chairman. Mr. Chess also currently works at Nektar Therapeutics, as Chairman from 2007, Issio Solutions, Inc., as Director from 2023, Twist Bioscience Corp., as Lead Independent Director from 2018, Bio Ventures for Global Health, as Director, NanOasis, Inc., as Director from 2012, Pelvalon, Inc., as Director, Twist Bioscience, as Director, BigHat Biosciences, Inc., as Director from 2022, California Institute of Technology, as Trustee from 2006, and Committee for Economic Development, as Trustee. Mr. Chess also formerly worked at OPX Biotechnologies, Inc., as Chairman & Chief Executive Officer from 2007 to 2015, Germitec SA, as Chairman, Pharsight Corp., as Director from 2000 to 2006, CymaBay Therapeutics, Inc., as Director in 2009, CoTherix, Inc., as Director from 2004 to 2007, Biotechnology Innovation Organization, as Director in 2009, The White House, as Associate Director-Economic & Domestic Policy from 1990 to 1991, Intel Corp., as Principal, and Metaphor Computer Systems, Inc., as Principal. Mr. Chess received his Masters Business Admin degree in 1980 from Harvard University and undergraduate degree from California Institute of Technology. |
| Howard W. Robin |
Howard W. Robin is currently the President, Chief Executive Officer & Director at Nektar Therapeutics since 2007. He is also a Trustee at Fairleigh Dickinson University. Previously, he served as the President, Chief Executive Officer & Director at Sirna Therapeutics, Inc. from 2001 to 2006. Prior to that, he was the Director-Business Planning & Development at Berlex, Inc. from 1987 to 2001. He has also held positions as a Director at Acologix, Inc., Biotechnology Innovation Organization, and The Bay Area Bioscience Association. Additionally, he worked as a Senior Associate at Arthur Andersen LLP. From 1991 to 2001, he served as the Vice President & General Manager at Berlex Laboratories, Inc. Mr. Robin obtained his undergraduate degree from Fairleigh Dickinson University in 1974. |
| Diana M. Brainard |
Diana M. Brainard is currently the Chief Executive Officer & Director at AlloVir, Inc., an Independent Director at Nektar Therapeutics, an Independent Director at Affinia Therapeutics, Inc., and an Executive Partner at MPM BioImpact, Inc. Previously, she worked at Gilead Sciences, Inc. as the Senior VP-HIV & Emerging Viral Infections from 2015 to 2021. Dr. Brainard received her undergraduate degree from Brown University in 1992 and her doctorate degree from Tulane University School of Medicine in 1997. |
| R. Scott Greer |
R. Scott Greer, as managing director of Numenor Ventures, LLC, is a private investor in and consultant to the life sciences industry with over 30 years experience. Mr. Greer has made direct investments in over 25 healthcare, technology, and consumer product companies. He was a founder of Abgenix, Inc., a publicly traded biotechnology company focused on developing and commercializing human antibody based therapeutics, serving as its Chief Executive Officer from its inception in 1996 through 2002 and as its Chairman of the Board from 2000 until 2006. Mr. Greer was an investor in and Chairman of the Board of Sirna Therapeutics. He was a director of and investor in Auspex Pharmaceuticals. Prior to forming Abgenix, Mr. Greer spent five years at Cell Genesys, Inc., a publicly traded biotechnology company, initially as Chief Financial Officer and Vice President of Corporate Development through its early development and initial public offering, and later as Senior Vice President of Corporate Development. Mr. Greer also held various positions at Genetics Institute, Inc.
Mr. Greer is currently a director of several public biopharmaceutical and medical device companies including: Nektar Therapeutics (Nasdaq: NKTR), StemCells, Inc. (Nasdaq: STEM), Versartis, Inc (Nasdaq: VSAR), Inogen, Inc. (Nasdaq: INGN), and Sientra, Inc. (Nasdaq: SIEN). He is also Chairman of the Board of Calimmune, Inc. In the past he was a director of Illumina, Inc. (Nasdaq: ILMN), CV Therapeutics, Inc. (Nasdaq: CVTX), Affymax, Inc. (Nasdaq: AFFY), Auspex, Inc. (Nasdaq: ASPX), BAROnova, Inc., Chimeros, Inc., and Anaptys BioScience, Inc. He also served as Chairman of the Board of Inogen, Inc. and Ablexis, Inc.
Mr. Greer has a B.A. in economics from Whitman College and an M.B.A. from Harvard University.
Mr. Greer served on the board of the Santa Barbara Maritime Museum from 2003-2006. |
| Roy A. Whitfield |
Roy A. Whitfield is the founder. He founded Incyte Corp. in 1991 and served as the Director from 2003 to 2014. He is currently the Lead Independent Director at Nektar Therapeutics since 2000. Mr. Whitfield has also held former positions as the Executive Chairman at BioSeek, Inc., Director at Station X, Inc., Director at Sciona, Inc., Principal at The Boston Consulting Group, Inc., Advisor at InterWest Partners LLC, and Principal at Cooper Biomedical, Inc. He was also an Independent Director at Illumina, Inc. from 2007 to 2017 and a Director at Solexa, Inc. from 2006 to 2007. Additionally, he served as the Principal at Technicon Instruments Corp. from 1984 to 1989. In terms of education, Mr. Whitfield holds an MBA from Stanford University and an undergraduate degree from the University of Oxford. |
| Myriam J. Curet |
Myriam J. Curet is currently an Independent Director at Nektar Therapeutics, Stereotaxis, Inc., and Inspire Medical Systems, Inc. She also serves as the Chief Medical Officer & Executive Vice President at Intuitive Surgical, Inc. Her former positions include Deputy Director-Medical at Gallup Indian Medical Center, Associate Professor-Surgery at The University of New Mexico, and Professor at Stanford University School of Medicine. Dr. Curet completed her undergraduate studies at Bryn Mawr College and obtained her doctorate degree from Harvard Medical School. |
| Jeffrey Robert Ajer |
Jeffrey Robert Ajer is an Independent Director at Nektar Therapeutics since 2017. He is also the Chief Commercial Officer & Executive VP at BioMarin Pharmaceutical, Inc. since 2005. Previously, he worked as the Director-Purchasing Worldwide at Bausch Health Americas, Inc. from 1986 to 1999. He also held positions at SangStat Medical Corp., True North Therapeutics, Inc., and Genzyme Corp. In terms of education, Mr. Ajer completed his undergraduate degree and MBA at the University of California, Irvine. |
